Thursday, September 9, 2021

ADARx Takes $75M For RNA Therapeutics

San Diego-based ADARx Pharmaceuticals, a biotechnology company which is developing RNA targeting therapeutics, said Wednesday that it has raised $75M in a Series B funding. The funding was co-led by SR One Capital Management and OrbiMed Advisors, and also included Sirona Capital and Lilly Asia Ventures. According to the company, the funding will go to advance

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.